🔎 Trials Near Me

Home › Myelofibrosis › Michigan › Ann Arbor

Myelofibrosis clinical trials in Ann Arbor, MI

8 studies for Myelofibrosis are looking for participants at sites in and around Ann Arbor (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

RecruitingPhase 1/2
  • University of Michigan, Ann Arbor
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04176198

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

RecruitingPhase 1/2
  • University of Michigan, Ann Arbor
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198

Quantitative MRI for Myelofibrosis

RecruitingObservational study
  • University of Michigan Hospital, Ann Arbor
Ages 18 to 99 · All sexes · Updated Jul 31, 2026 · NCT01973881

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

RecruitingPhase 2
  • GSK Investigational Site, Ann Arbor
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06517875

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

RecruitingPhase 3
  • University of Michigan ( Site 6000), Ann Arbor
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06351631

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, Ann Arbor
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

RecruitingPhase 3
  • University of Michigan Hospital, Ann Arbor
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135

Myelofibrosis trials in other cities

Other studies in Ann Arbor

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.